Study Summary
This is a Phase 1/2 multicenter, open-label, single dose trial of SP-101 investigational gene therapy in adults with CF who are ineligible for or intolerant to CFTR modulator therapy.
Want to learn more about this trial?
Request More InfoInterventions
SP-101 and doxorubicin Cohort 1COMBINATION_PRODUCT
Single inhaled dose of SP-101 and doxorubicin Dose 1
SP-101 and doxorubicin Cohort 2COMBINATION_PRODUCT
Single inhaled dose of SP-101 and doxorubicin Dose 2
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| University of Kansas Medical Center | Kansas City | Kansas | United States |
| Boston Children's Hospital, Brigham & Women's Hospital | Boston | Massachusetts | United States |
| Columbia University | New York | New York | United States |
| Hospital at University of Pennsylvania | Philadelphia | Pennsylvania | United States |